| ARIZONA BIOMEDICAL RESEARCH COMMISSION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120108521 | IMMUNOSTIMULATORY COMPOSITIONS AND USES THEREOF - The present invention provides novel immune-stimulatory polypeptides, and methods for their use and identification. | 05-03-2012 |
| 20110014195 | USE OF THERAPEUTIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCER - MUC1 (DF3, CD227, episialin, PEM) is a heavily O-glycosylated heterodimeric protein of >300 kDa, normally expressed abundantly on the apical surface of glandular epithelia. MUC1 mimetic peptides are selectively retained in mammary gland tumors, colon and skin after systemic administration. Moreover, MUC1 mimetic peptides reduce tumor initiation. In addition, MUC1 mimetic peptides can be used in conjunction with other anti-EGFR treatments in the adjuvant context, i.e., after surgery. | 01-20-2011 |
| 20100291096 | THERAPEUTIC PEPTIDES FOR THE TREATMENT OF METATSTATIC CANCER - Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect. | 11-18-2010 |
| 20100222380 | Modified Chalcone Compounds as Antimitotic Agents - Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN-COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an α,β-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients. | 09-02-2010 |
